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Background: Radiotherapy and cyclophosphamide-induced haemorrhagic cystitis are rare but severe complications
occurring in 3–6% of patients. Hyperbaric oxygen treatment (HBOT) has been demonstrated to be an effective treatment
for haematuria not responding to conventional management. Only very few data exist for long-term follow-up
after HBOT.
Methods: We retrospectively reviewed 15 patients referred for HBOT for haemorrhagic cystitis (HC). HBOT was
performed for 130 min/day at a pressure of 2.4 atmospheres. We evaluated patient demographics, type of
radio- and chemotherapy and characteristics of haematuria. The effect of HBOT was defined as complete or
partial resolution of hematuria according to the RTOG/EORTC grade and Gray score.
Results: A total of 15 patients (12 after radiotherapy, two after chemotherapy and one patient with a combination of
both) were treated with a median of 34 HBO treatments. Radiotherapy patients received primary, adjuvant, salvage and
HDR radiotherapy (60 – 78 Gy) for prostate, colon or cervical cancer. The patient with combination therapy and both of
the chemotherapy patients were treated with cyclophosphamide. First episodes of haematuria occurred at a median of
48 months after completion of initial therapy. The first HBOT was performed at a median of 11 months after the first
episode of hematuria. After a median of a 68-month follow-up after HBOT, 80% experienced a complete resolution and
two patients suffered a singular new minor haematuria (p < 0.00001). A salvage-cystectomy was necessary in one patient.
No adverse effects were documented.
Conclusions: Our experience indicate that HBOT is a safe and effective therapeutic option for treatment-resistant
radiogenic and chemotherapy-induced haemorrhagic cystitis. For a better evaluation prospective clinical trials
are required.
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Radiotherapy-induced haemorrhagic cystitis (RHC) after
pelvic radiation therapy is a rare but known long-term
complication which develops in 3–6.5% of patients. RHC
can occur from 6 months to 20 years after radiation therapy
[1-3]. Chemotherapy-induced haemorrhagic cystitis (CHC)
can also cause chemotherapy-limiting haematuria (cyclo-
phosphamide or others oxazaphosphorines) [4-7]. Since the* Correspondence: stephan.degener@helios-kliniken.de
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thiol compound, for uroprotection the incidence of CHC
has decreased to less than 5% [5]. Despite the underlying
cause, HC is a relevant impairment of the patients’ quality
of life with often multiple and mostly emergency admis-
sions to hospitals.
As for other severe haematurias, bladder irrigation is
the primary treatment for HC. Different systemic or
intravesical agents such as hyaluronic acid, aminocaproic
acid, formalin or prostaglandins have been used, how-
ever with limited success [8]. As a consequence, bladder
fulguration is repeatedly used as a therapeutic option toal. This is an Open Access article distributed under the terms of the Creative
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the most severe cases selective embolization of the
hypogastric arteries or salvage cystectomy with urinary
diversion may be necessary [9].
Hyperbaric oxygen therapy (HBOT) is a promising but
still extreme rarely-used therapeutic option for patients
in whom the standard management has failed. By in-
creasing the tissue oxygen level by up to 15-fold, HBOT
promotes capillary angiogenesis which also increases the
regeneration of damaged urothelium. Studies report suc-
cess rates of 73 to 96% [1,3,10-13]. We present here our
results of HBOT for the treatment of RHC and CHC.Methods
We retrospectively reviewed all 23 patients treated with
HBOT for haemorrhagic cystitis between 01/2002 and
10/2014 in two urological departments. In 15 patients a
complete follow-up was achievable. Patient demographics
were recorded, as was for RHC the total radiation dosage
and the type of radiation therapy. Follow-up was ensured
by outpatient contacts in the clinic and by cooperating
ambulatories. Each patient gave informed consent and the
study was approved by the institutional review committee
of Witten/Herdecke University.Evaluation of hematuria
Initially, all patients underwent permanent bladder irri-
gation and evacuation of blood clots. Urine cultures
were set up before irrigation to detect infectious haema-
turia. When urine cleared after bladder irrigation patients
underwent a cystoscopy or, in cases of heavy bleeding, a
transurethral resection / fulguration to rule out an urothe-
lial carcinoma (including carcinoma in situ). Additionally,
the upper urinary tract was evaluated to exclude it as a
source of bleeding.
The onset of the first relevant haematuria and the
maximum severity of all haematuria episodes were eval-
uated. The grading of haematuria was determined from
the RTOG/EORTC grade for RHC, and the Gray score
for CHC [14,15] (Table 1). The difference in haematuria
grade before and after treatment was analyzed by using aTable 1 Classification scores for radiotherapy and chemother
Gray scores (modified from [14] and [15])













Grade 0 Grade 1
Normal, no haematuria Mild haem
or dilatatipaired t-test. Statistical significance was selected as a
value of p < 0.05.
Hyperbaric oxygen therapy
Hyperbaric oxygen therapy was initiated when conven-
tional therapy options remained unsuccessful and when
no contraindication for HBOT was given (assessment
with otoscopy, spirometry and ECG). We evaluated the
time between the first haemorrhagic episode and the be-
ginning of HBOT, the number of HBOTs and all HBOT-
related data (Table 2).
All patients were treated in the same HBOT centre
where HBOT was performed in a treatment chamber with
a capacity of up to 12 patients (Haux Starmed, HAUX-
LIFE-SUPPORT GmbH, Karlsbad-Ittersbach, Germany)
(Figure 1) under continued monitoring. The therapy
scheme TS240-90 [16] is composed of 3x30 minute periods
of pure oxygen (at a pressure of 2.4 atmospheres). The epi-
sodes of pure oxygen were interrupted by 10 minutes with
normal air (21% (v/v) oxygen) to reduce oxygen toxicity
(Figure 2). The increase of the partial pressure of oxygen
(pO2) was measured percutaneously. HBOT was performed
five days a week. After each HBOT session the grade of
haematuria was evaluated and patients were checked for
barotraumas.
The effect of HBOT was defined as complete (no fur-
ther macro-haematuria until completion of follow-up)
or partial resolution of haematuria (defined as a lower
RTOG/EORTC or Gray score than before HBOT).
Results
In 15 patients (12 males, 3 females) undergoing HBOT
for therapy-resistant haemorrhagic cystitis between 2002
and 2014 a complete retrospective follow-up was achieved.
Additionally, two patients suffered from haemorrhagic
proctitis. At the beginning of HBOT the age ranged from
22 to 86 years (mean age 71). At the end of follow-up the
age ranged from 33 to 90 years (mean age 76 y).
Radiotherapy was performed owing to prostate (10 pa-
tients, 67%), colon or cervical cancer (1 patient each, 7%).
One patient underwent combined radio-chemotherapy
owing to retroperitoneal synovial sarcoma (with Ifosfamide,apy induced haemorrhagic cystitis: RTOG/ EORTC and
orrhagic cystitis
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aturia with telangiectasia











































M 68 70 PCA adj RC 08/2008 34 3 5 0 4 40 33 no relapse 0
M 82 86 PCA prim RC 07/2004 54 3 3 0 15 24 53 no relapse 0




W 71 83 CCA adj RC 07/1997 30 3 3 0 28 128 142 no relapse 0
M 80 86 PCA prim RC 07/1998 5 4 2 2 110 40 78 no relapse 0
M 71 76 PCA adj RC 01/1999 76 4 2 1 36 35 28 no relapse,
†2010
0
W 86 90 UCA adj RC 01/1990 234 4 3 2 0 6 29 no relapse,
†2012
0
M 80 83 PCA adj RC 01/2000 124 4 3 3 1 51 16 SRC 2010,
†2012
4
M 65 72 PCA adj RC 03/2000 50 4 3 1 30 26 94 no relapse 0
M 61 63 PCA sal RC 02/2010 20 4 3 4 7 20 133 no relapse 0
M 22 33 RPSS comb RC/CC 01/1999 43 4 2 12 11 34 28 no relapse 0
M 73 78 PCA sal RC/RP 07/2007 14 3 2 2 1 48 68 no relapse 0
M 65 71 PCA adj RC/RP 07/2003 48 4 3 2 3 20 49 no relapse,
†2011
0


















Figure 1 Exterior and interior view on the pressure chamber for max. 12 persons.
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phosphamide for Wegener’s granulomatosis or Lupus
erythematosus.
In 7 patients (47%) radiotherapy was performed as an
adjuvant because of prostate, colon or cervical cancer
(60–64 Gy). Primary and salvage radiation was applied
to two patients (13%) for prostate cancer (66 and 70 Gy)
and one patient (7%) was treated with HDR brachytherapy
(78 Gy) for prostate cancer. The radiation dose of the pa-
tient with retroperitoneal synovial sarcoma was 66 Gy.
The first episodes of haematuria occurred between 5
and 362 months (median 48 months) after the beginning
of radiation or chemotherapy. A median of three (2 – 5)
admissions to the hospital and up to seven outpatient
treatments were necessary. According to the RTOG/
EORTC score haemorrhagic complication Grade 4 oc-
curred in nine patients (60%) and Grade 3 in four (27%).
Patients with CHC had haemorrhagic complication Grade
3 or 4 respectively (Gray score). Blood transfusions (be-
tween 1 and 12 units) were necessary in 11 patients (73%).
In all patients urothelial malignancy was excluded by
histology. At least one bladder fulguration was per-
formed in every case in order to stop the bleeding but
no patient received any intravesical instillation therapy.
When HC was resistant to conventional therapy (without
instillation therapy) HBOT was initiated, in a median of
eleven months (0 – 110) after the first episode of haema-
turia. Between 6 and 128 HBOT sessions (mean 34) were
necessary to achieve a total resolution of haematuria. In allFigure 2 Diagram of the therapy scheme TS 240–90. “Air” is defined as no
application of 100% (v/v) oxygen. The pressure [atmosphere] is plotted onHBOT sessions the partial pressure of oxygen measured
percutaneously was increased to 1250–1480 mmHg.
Follow-up ranged from 16 to 142 months (mean 68).
In 12 patients (80%) a total resolution of the HC could
be achieved without any further haematuria. In two pa-
tients (13%) bladder irrigation had to be re-performed
once for a singular recurrence of haematuria (RTOG/
EORTC Grade 3). Changes in RTOG/EORTC scores
were statistically significant (p < 0.00001).
In one case a salvage cystectomy with urinary diver-
sion (ileum conduit) was necessary owing to a fulminant
bleeding episode. The overall success rate was 93%. The
radiogenic proctitis completely recovered in both cases.
No side effects were noted in any patient.
Discussion
Radiation and cyclophosphamide-induced HC is a severe
and potentially life threatening complication. Management
can be highly challenging with well-known urological treat-
ment options. It is to be expected that the number of radi-
ation therapies will increase during the next decades [17].
In parallel a rise in complications and side effects, such as
RHC, can be expected. The results of this study suggest
that HBOT is a promising option in therapy-resistant HC
with a success rate of more than 90%.
In both CHC and RHC the acute reaction on urothelial
damage is an inflammatory response causing oedema, ul-
ceration, neovascularisation and haemorrhagic necrosis.
This is usually limited to the treatment period.rmal ambient air with 21% (v/v) oxygen. “Oxygen” is defined as the
the y-axis, the treatment time [min] on the x-axis (adopted from [24]).
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tion of acrolein, metabolites of oxazaphosphorine alkylated
drugs. There is no clear dose-related relationship. Since the
1970s the prophylactic application of Mesna has been used
as a standard protocol for prevention of haemorrhagic
complications. It neutralises acrolein and its toxic effects to
the urothelium. The incidence of CHC is reduced from
about 68% to about 5% [5].
In RHC urothelial damage is caused by radiolysis of
water. The concentration of activated free oxygen radi-
cals increases; as these are highly reactive, they cause cell
membrane injury by lipid peroxidation, which induces
immediate cell death. Additionally, direct (by radiation
energy) and indirect (by oxygen radicals) DNA damage
causes replication failures resulting in delayed cell death
[8]. This damage is dose-related.
This acute reaction can escalate into a chronic end-
arteritis which seems to be the determining pathology of
late-onset RHC and has been described as the “three-H
model”: the progressive endarteritis and vascular rarefac-
tion (hypovascular) results in critical ischaemia (hypoxia)
with a reduction in oxygen concentration of up to 70-80%.
Ischaemia of the mucosal tissue can lead to necrosis and
sloughed off cells because of impaired healing capacity. A
compensatory teleangiectasia develops and causes (persist-
ent) haematuria. Finally, fibrotic repair processes can lead
to impaired bladder capacity (hypocellular) [3,11]. This
process can still become relevant up to 20 years after radi-
ation therapy [2]. In our study haematuria occurred in a
median of 41 months after completion of radiation ther-
apy. This is within the range of previously described
periods of 35–48 months [1,2,8,10].
Tissue oxygen supply occurs primarily via diffusion
from the capillaries by significantly increasing the physically
dissolved oxygen in the plasma (100% O2 pressure of 1.4 at-
mosphere). HBOT improves the local and regional tissue
oxygen supply. Our results demonstrate a drastically in-
creased pO2 in the tissue from 1250 to 1480 mmHg from
percutaneous measurements. By increasing pO2, macro-
phages, fibroblasts and granulocytes may resume their nor-
mal function and mediate repair processes. In addition,
HBOT directly induces neo-angiogenesis, whereby 80% of
the normal capillary density can be achieved. Furthermore
HBOT causes anti-oedematous vasoconstriction without
secondary ischaemic hypoxia [18-20].
Hyperbaric oxygen in patients with severe RHC or
CHC not responding to conventional urological treatment
is an extremely rare and not yet standardised treatment
option.
In RHC different research groups and we have reported
success rates between 75 and 96% in both prospective and
retrospective study designs [10,13,19,21-23]. In contrast to
our study, other cohorts have varied between 13–60 pa-
tients with only short follow-up periods of 12–30 months.We could demonstrate a success rate of 90% even after
a median long-term follow-up period of 68 months, con-
firming the excellent long-term results reported by
Nakada et al. whose success rate was 75-88% [12].
Only a few cases patients with CHC have been re-
ported. One of the larger series with six CHC patients
reported a 100% success rate after 11 to 36 months of
follow-up (although they noted that in one patient
haematuria recurred after three months) [24]. In other re-
ported case reports a complete loss of haematuria occurred
after a follow-up period of 11–36 months [7,24-26].
The main advantage of this therapy is that there are
no severe side-effects. The most common adverse effects
of HBOT are middle ear or sinus barotraumas requiring
myringotomy in up to 5% [27]. Reversible myopia has
also been described as a dose-dependent HBOT side ef-
fect [27]. Our study, as many other reports, did not
show any adverse effects of HBTO.
So far variable success of HBOT has been discussed
without any clear results, mainly because of the small
sample size in most series.
In RHC the total radiation dose seems to have an in-
fluence on HBOT success: generally, complications such
as RHC begin at a total dosage of 45–55 Gy and increase
significantly at a cumulative dose of ≥60 Gy (≥5% with
late effects) [28]. Nakada et al. showed a significantly
better HBOT success in patients exposed to lower radi-
ation doses (62Gy vs. 76Gy, p < 0.001). In addition del
Pizzo et al. reported relatively poor HBOT long-term
success rates (27% after 5 years) in patients with high
dosage radiotherapy (75Gy) [29]. In the present study
most of the patients received a cumulative dose between
60 – 66Gy. One patient with high dose therapy (78 Gy)
suffered one unique relapse of haematuria.
Some authors discuss that there might be an influence
of the number of HBOT sessions on the therapeutic suc-
cess in RHC. Most of the studies applied between 30
and 40 treatment sessions [13,19,21,29] which is com-
parable to our data with a median of 34 treatments. The
significantly higher number of HBOTs (62) may be the
reason for the excellent long-term success in Nakada’s
study compared with a study with a success rate of 64%
after only 14 HBOTs [30]. The few existing data suggest
that fewer HBOTs are sufficient in CHC patients. The
reported series of six CHC cases required a median of
27 HBOTs, other published cases between 14 and 40
treatments [7,24-26].
The period of time between the onset of haematuria
and the beginning of HBOT is discussed as another suc-
cess factor for RHC. In some studies, patients with a
shorter pre-treatment interval (6–8 months) showed sig-
nificantly better results on HBOT (p <0.001) [12,13]. We
could not demonstrate any relationship between the
time to beginning of HBOT and its success. This is most
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HBOT was started at a mean of 47 days after the onset
of symptoms. However, intervals of up to four months
between first admission and the beginning of HBOT
have been described [24].
Finally the influence of patient age is controversially
discussed. Some studies suggest that younger patients
(≤70 years) have higher success rates. Other studies, as
well as ours, have not found any correlation between age
and HBOT success. Furthermore, in CHC patients a
complete remission of haematuria is reported in cases
aged from 15 to 82 years [1,12,13,24-26].
The costs amount to approximately €200 per HBOT
session. Accordingly, the median costs per patient in this
study were €6,800 (34 HBOT sessions). The costs are
comparable to a cost-analysis case study from Australia
which showed HBOT to provide major health cost sav-
ings [31].
Our study, as many others, is certainly limited by the
small study population and the retrospective design. Fur-
thermore different treatment protocols reduce the com-
parability of treatment outcomes. Prospective trials would
be desirable for further evaluation but the first planned
prospective and randomized study (initiated by the Baro-
medical Research Foundation) was cancelled because of
poor recruitment (NCT00134628). Nevertheless, we be-
lieve that our results show the long-term efficiency and
safety of this therapy option in patients suffering from
radiation- and cyclophosphamide-induced haemorrhagic
cystitis.
Conclusions
Our data suggest that hyperbaric oxygen therapy is a
safe and simple therapy option with a long-term success
rate of approximately 90% with hardly any side-effects.
Therefore HBOT should be considered more often in
cases of severe haemorrhagic cystitis induced by radiation
and/or cyclophosphamide.
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